Bayer’s Early R&D And Animal Health To Get Boost After Material Sciences Sell-Off
This article was originally published in The Pink Sheet Daily
Executive Summary
Germany’s diversified big pharma company will be getting a bit more focused, with the goal of aiding its faster growing segments.
You may also be interested in...
Novartis Thinks It Can Do Better With GSK’s Oncologics Than GSK Did
Novartis stresses the blockbuster potential, in its hands, of three products – Votrient, Tafinlar and Mekinist – that it is acquiring from GSK as part of its narrowed focus on innovative pharmaceuticals, eye care and generics, and the divestment of vaccines, OTCs and animal health.
Ahead Of Schedule, Pfizer Prepares To Set Zoetis Free In Stock Swap
The Big Pharma intends to loosen its leash on its former animal health business come June when Pfizer shareholders will be given an option to swap their shares for Zoetis stock. Meanwhile, Pfizer continues its strategy to shift its focus back to the core pharmaceutical business.
Pipeline Watch: Phase III Readouts in Wilson Disease, Parkinson's Disease And COVID-19
Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.